KHẢO SÁT HIỆU QUẢ CỦA BEVACIZUMAB TIÊM NỘI NHÃN ĐIỀU TRỊ PHÙ HOÀNG ĐIỂM TRÊN BỆNH NHÂN BỆNH VÕNG MẠC ĐÁI THÁO ĐƯỜNG TĂNG SINH

Abstract

Objectives: To evaluate the effectiveness of intravitreal Bevacizumab injection on macular edema with proliferative diabetic retinopathy (PDR). Methods: Prospective descriptive study on 48 eyes of 32 patients with proliferative diabetic retinopathy treated with three consecutive monthly 1,25 mg/ 0,05 ml intravitreal Bevacizumab injections at Le Van Thinh Hospital from 12/2023 to 08/2024. Followed up 3 months. Results: The mean age is 59,69 ± 10,61 years. The mean diabetic duration is 7,15 ± 4,84 years. mean HbA1C 7,55 ± 1,72 %. LogMAR visual acuity (VA) improved after treatment, with mean VA before treatment being 0,74 ± 0,68 and after 3 months being 0,54 ± 0,59. The percentage of patients with improved vision is 52,1%. Central macular thickness (CMT) decreased by a mean of 84,86 µm. Macular volume (MV) decreased by a mean of 1,6 mm³. The foveal avascular zone (FAZ) size decreased by a mean of 0,098 mm². Vascular density (VD) in the superficial capillary perfusion (SCP) increased in all regions. The fovea area has the earliest and greatest improvement in vascular density. A significant correlation exists between logMAR VA after 3 months with diabetic durations, CMT, and FAZ size. There was no correlation between logMAR VA after 3 months with VD SCP. No serious ocular or systemic complications were observed immediately after injection, after 1 week, 1 month, and 3 months of intravitreal injection of Bevacizumab. Conclusions: Intravitreal 1,25 mg/0,05 ml Bevacizumab therapy in the treatment of macular edema with proliferative diabetic retinopathy improve significantly retinal function and structure after 3 months.